

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-6. (canceled)

7. (previously presented) An immunostimulatory HER-2 fusion protein comprising:  
a polypeptide or protein antigen sequence component and a sequence component derived from the intracellular domain of the HER-2 protein, said fusion protein is selected from the group consisting of HER500 (SEQ ID NO: 1), HER500•hGM-CSF (SEQ ID NO: 2), HER500\* (SEQ ID NO:3) and HER500\*•rGM-CSF (SEQ ID NO: 4), where said fusion protein is effective to elicit a cellular immune response to the polypeptide or protein antigen sequence component of the fusion protein.

8. (original) The immunostimulatory HER-2 fusion protein of claim 7, where the fusion protein is HER500•hGM-CSF (SEQ ID NO: 2).

9-11. (canceled)

12. (currently amended) A method of producing superactivated DC, by exposure to an immunostimulatory fusion protein, comprising:

exposing a dendritic cell (DC) or dendritic cell precursor (DCP) to the an immunostimulatory fusion protein of claim 7 comprising a polypeptide or protein antigen sequence component and a sequence component derived from the intracellular domain of the HER-2 protein, in a manner effective to result in a cellular immune response to the polypeptide or protein antigen sequence component of the fusion protein.

13. (original) The method of claim 12, where said exposing takes place *in vitro*.

14. (original) The method of claim 12, where said exposing takes place *in vivo*.

15-19. (canceled)